Statin induced myopathy
Published 6 November 2008, doi:10.1136/bmj.a2286
Cite this as: BMJ 2008;337:a2286
Sivakumar Sathasivam, consultant in neurology, Bryan Lecky, consultant in neurology
1 Department of Neurology, Walton Centre for Neurology and Neurosurgery, Liverpool L9 7LJ
from Jules: in light of recent JUPITER Study findings reporting reduced cardiovascular events using Crestor in men over 50 yrs old and women over 60 yrs old with normal lipids & apparently healthy, here is information regarding the risk for myopathy associated with statin use. This article discusses pre-existing risk factors for myopathy including creatine kinase levals, the authors suggest looking at your creatine kinase before embarking on statin therapy, and other risk factors are discussed below. It sounds to me that having HIV appears to be a risk factor for myopathy so if we ever get aging studies off the ground our researchers should evaluate rates of myopathy and potential causes.
Since their introduction for the treatment of hypercholesterolaemia in 1987, the use of statins has grown to over 100 million prescriptions per year.1 About 1.5-3% of statin users in randomised controlled trials and up to 10-13% of participants enrolled in prospective clinical studies develop myalgia.1 2 3 4 As a conservative estimate, at least 1.5 million people per year will experience a muscle related adverse event while taking a statin. In this review we discuss statin induced myopathy and its management in the light of recent epidemiological studies, randomised controlled trials, and guidelines.
Four types of muscle disorders are associated with statins: myalgia, myositis, rhabdomyolysis, and asymptomatically increased creatine kinase
Although the rate of statin induced myopathy among statin users is low, the high volume of statin prescriptions means that the condition is commonly encountered in clinical practice
Statin-induced myopathy correlates most closely with the dose of statins, but any factor that increases the serum concentration of a statin potentially increases the risk of myopathy
If a patient presents with features suggesting statin induced myopathy, first line management is to stop statin therapy and observe any effect on symptoms and concentration of creatine kinase
Current research includes examining the role of genetic factors in statin induced myopathy, the effectiveness of treatments such as coenzyme Q10, the effect of statins on muscle performance, and the mechanisms of statin induced myopathy.
Additional educational resources
Resources for healthcare professionals
National Lipid Association (www.lipid.org)-provides various guidelines on statin therapy
McKenney JM. Report of the National Lipid Association's Statin Safety Task Force. Am J Cardiol 2006;97(suppl):S1-98
Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002;106:1024-8
Resources for patients
Statins (www.patient.co.uk/showdoc/40024969)-overview of statins from Patient UK website
Tips for non-specialists
Slightly increased creatine kinase is common in the general population
Myopathy that develops after a patient has been taking statins for several years is unlikely to have been caused by these drugs
Thyroid stimulating hormone should be checked in patients on statins who develop a myopathy because hypothyroidism is a common cause of hypercholesterolaemia and raised creatine kinase
If muscle-related symptoms or raised creatine kinase concentrations persist after statin therapy is stopped, consider further investigations such as electromyography and muscle biopsy, in conjunction with a specialist
How common is statin induced myopathy?
In one large, population based cohort study of patients from general practices in the United Kingdom between 1991 and 1997, the mean incidence of myopathy (defined in this trial as muscle weakness and raised concentrations of creatine kinase) in patients taking statins was 1.2 per 10 000 person years (95% confidence interval 0.3 to 4.7).5 In another large study that examined rhabdomyolysis in a hospital population, the average incidence per 10 000 person years for monotherapy with atorvastatin, pravastatin, or simvastatin was 0.44 (0.20 to 0.84) and for cerivastatin was 5.34 (1.46 to 13.68).6
What is the clinical spectrum of statin induced myopathy?
The clinical spectrum of statin induced myopathy includes myalgia, myositis, rhabdomyolysis, and an asymptomatic increase in the concentration of creatine kinase. Muscle related adverse events can be difficult to describe because the terminology used is inconsistent, but the proposed definitions in the tableGo provide a useful guide. The term myopathy is often used to include the entire spectrum of muscle related adverse events (as in this article), but other definitions are common, especially when the term is used in clinical trials.
What are the clinical features of statin induced myopathy?
Symptoms of statin induced myopathy include fatigue, muscle pain, muscle tenderness, muscle weakness, nocturnal cramping, and tendon pain. The muscle symptoms tend to be proximal, generalised, and worse with exercise. In a small retrospective study of 45 patients, the mean duration of statin therapy before onset of symptoms was 6.3 (SD 9.3) months (range 1 week to 4 years). In this study, the mean duration of myalgia after stopping statin therapy was 2.3 (SD 3.0) months (range 1 week to 4 months).7 Muscle symptoms that develop in a patient who has been taking statins for several years are unlikely to have been caused by these drugs.
What are the proposed mechanisms of statin induced myopathy?
The mechanism of statin induced myopathy is unknown. One proposal is that impaired synthesis of cholesterol leads to changes in the cholesterol in myocyte membranes and changes the behaviour of the membrane.8 However, inherited disorders of the cholesterol synthesis pathway that reduce cholesterol concentrations are not associated with myopathy.9 Another proposed mechanism is impaired synthesis of compounds in the cholesterol pathway-in particular deficiency of coenzyme Q10-which could lead to impaired enzyme activity in mitochondria.10 Although low serum concentrations of coenzyme Q10 have been noted in patients taking statins, concentrations in muscle have not consistently shown this pattern.11 A third proposed mechanism is depletion of isoprenoids-lipids that are a product of the hydroxymethyl glutaryl coenzyme A reductase pathway and that prevent myofibre apoptosis.12
What are the risk factors for statin induced myopathy?
Evidence from well designed randomised controlled trials shows that myopathy correlates most closely with dose of statins and is independent of reductions in low density lipoprotein cholesterol.13 Several risk factors have been proposed, mainly by experts on the basis of published evidence (box 1).14 15 No clear data are available about the relative risks associated with individual factors, since the dose, and possibly the type, of statin affects the risk of precipitating myopathy.
Box 1 Factors that may increase the risk of statin induced myopathy
Advanced age (>80 years old)
Low body mass index
Multisystem diseases (for example, diabetes mellitus)
Diseases affecting kidney or liver function
Drug interactions, especially with drugs that are inhibitors or substrates of the cytochrome P450 pathway (for example, fibrates, nicotinic acid, calcium channel blockers, ciclosporin, amiodarone, thiazolidinediones, macrolide antibiotics, azole antifungals, protease inhibitors, warfarin)
Major surgery or trauma
Diet (excessive grapefruit or cranberry juice)
Genetic factors (for example, polymorphisms of the cytochrome P450 isoenzymes or drug transporters, inherited defects of muscle metabolism, traits that affect oxidative metabolism of fatty acids)
Risk factors such as advanced age, female sex, low body mass index, diminished hepatic and renal function, multiple comorbidities or medications, excess alcohol, intercurrent infections, surgery or trauma, drug interactions, and dietary effects have been largely derived from clinical trials and through reporting of adverse events.14 15
Any factor that increases the serum concentration of a statin has the potential to increase the risk of myopathy. Therefore, factors that affect the pharmacokinetics of statins, leading to increased concentrations of the drugs in blood or tissue, may predispose to myopathy. Although evidence shows a link between increasing serum statin concentrations and muscle complaints, no direct link has been shown between intramuscular statin concentrations and myopathy.13 Pharmacodynamic factors, such as transporters affecting the bioavailability of statins, are probably important in determining toxicity, although no direct evidence has been found in humans. Drug responses can also be affected by predisposing genetic factors. For example, a cross sectional study of 136 patients with statin induced myopathy showed a higher prevalence of underlying metabolic muscle disease (deficiencies in myophosphorylase, carnitine palmitoyltransferase II, and myoadenylate deaminase) than expected in the general population.16 No definite evidence has been found that statins are harmful in patients with pre-existing non-metabolic myopathy.
In a small randomised controlled trial, concentrations of creatine kinase after treadmill exercise were significantly higher in patients assigned to lovastatin than in the placebo group. The authors of this study proposed that statins exacerbated exercise induced injury of skeletal muscles, but without tissue evidence from a muscle biopsy, this conclusion is debatable.17
Is the risk of myopathy equal for all statins?
In vitro and in vivo experiments suggest that lipophilic statins (for example, simvastatin, atorvastatin, lovastatin) are more likely to produce muscular effects than are relatively hydrophilic agents (such as pravastatin, rosuvastatin, and fluvastatin).18 Lipophilic compounds are more likely to penetrate into muscle tissue, enhancing the potential for myotoxic effects. One small observational study showed that pravastatin was associated with a lower incidence of myopathy than was the more lipophilic simvastatin in patients who underwent cardiac transplant.19 Therefore, it is prudent to use a more hydrophilic agent in patients with pre-existing muscle disease.
Is measuring baseline creatine kinase necessary before starting statin therapy?
The statin advisory panel of the American Heart Association and National Heart, Lung and Blood Institute recommend measuring creatine kinase before starting statin therapy, but the National Lipid Association's muscle expert panel does not consider this measurement necessary.13 14 A reasonable compromise would be to measure baseline creatine kinase in high risk groups, but it is unclear what constitutes an acceptable rise in creatine kinase after statins are started.20
To prevent unnecessary investigations, it is important to note that slightly raised concentrations of creatine kinase are common in the general population. In the Heart Protection Study, in which more than 20 000 people with cerebrovascular disease and other major vascular events were randomised to simvastatin or placebo, no significant difference in levels of creatine kinase was noted between the two groups for participants in whom creatine kinase was persistently raised up to four times the upper limit of normal.21
Creatine kinase concentrations differ between population subgroups. For example, creatine kinase concentrations have been found to be higher in black people than in white people.22 "Idiopathic hyperCKemia"-in which creatine kinase is raised in the absence of clinical or histological evidence of neuromuscular disease-is a genetically heterogeneous condition found in all ethnic groups and is more common in men than in women.23 Physical activity, especially when unaccustomed, and concurrent medical conditions, such as hypothyroidism, may also increase creatine kinase.
Does creatine kinase need to be monitored after statins are started?
Routine monitoring of creatine kinase in asymptomatic patients is not recommended by the American College of Cardiology/American Heart Association/National Heart, Lung and Blood Institute advisory committee and the National Lipid Association's muscle expert panel.13 14 In patients with muscle weakness or pain, creatine kinase should be measured to assess severity of muscle damage and aid in deciding whether to continue treatment, although in these patients a normal creatine kinase concentration does not necessarily rule out ongoing muscle damage related to statins.24
How is statin induced myopathy managed?
Box 2 Differential diagnoses of muscle related symptoms
If a patient's history, physical examination, and creatine kinase measurements show features of statin induced myopathy, first line management is to stop statins, observe symptoms, and monitor creatine kinase. A repeat challenge with statins may be attempted to assess whether features of statin induced myopathy return; many patients with myalgia or myositis will tolerate reintroduction of the same statin, preferably at a lower dose, after symptoms resolve.13
If muscular symptoms are tolerable and creatine kinase is not raised, or is less than 10 times the upper limit of normal, statins may be continued, with frequent monitoring of symptoms and creatine kinase, as long as symptoms are not progressive. In patients with tolerable muscle related problems and creatine kinase concentration more than 10 times the upper limit of normal, or in those with rhabdomyolysis, statin therapy should be discontinued and its risks and benefits should be assessed. An alternative class of lipid lowering drug might need to be considered, or statin therapy could be resumed if the benefits seem to outweigh the risks.
What is the role of electromyography?
No prospective studies have assessed the usefulness of electromyography in statin induced myopathy or have provided detailed electromyography findings in various manifestations of the condition. However, as a general point of good practice, electromyography is often done in conjunction with muscle biopsy in atypical cases of statin induced myopathy. Electromyography findings are commonly reported to show myopathic changes, usually in the proximal muscles, in agreement with clinical findings.
When is muscle biopsy necessary?
Although muscle biopsy is not routinely needed for statin induced myopathy, it may be helpful in atypical cases; advice from a specialist is desirable. Persistent muscular problems or raised creatine kinase after statins have been withdrawn; this should prompt investigation for other causes of myopathy (figure)Go.25Muscle pathology in statin induced myopathy is non-specific, with necrosis, degeneration, and regeneration of fibres and phagocytic infiltration. In some cases, lipid filled vacuoles, subsarcolemmal accumulations, cyclo-oxygenase negative fibres, and ragged red fibres are seen.26 Ultrastructural skeletal myocyte damage includes the breakdown of the T-tubular membranes and subsarcolemmal fissuring (separating the myofilaments from the plasma membrane, but leaving the plasma membrane intact). These changes occur even in patients who do not have symptoms.27
Does coenzyme Q10 have a role in treating statin induced myopathy?
Reports of myocellular concentrations of coenzyme Q10 in patients being treated with statins therapy have noted increased, decreased, and unchanged levels.28 Therefore, the usefulness of this compound in statin-induced myopathy is unclear. In one small randomised double blind trial, 41 patients taking statins who had muscle pain received either coenzyme Q10 or vitamin E. After one month of treatment, 18 of 21 patients taking coenzyme Q10 reported improvement in muscle pain, compared with three of 20 taking vitamin E (P<0.001).29 More studies, though, are needed before coenzyme Q10 can be recommended for this condition.14
Sources and selection criteria
We searched PubMed using the term "statin" in conjunction with "myotoxicity", "myopathy", "myalgia", "myositis" and "rhabdomyolysis". Where necessary, we made additional searches relating to the themes highlighted by the original search.
1. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006;97(suppl 8A):52-60C.
2. Bays H. Statin safety: an overview and assessment of the data-2005. Am J Cardiol 2006;97(suppl 8A):6-26C.[CrossRef]
3. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 2005;19:403-14.[CrossRef][ISI][Medline]
4. Scott RS, Lintott CJ, Wilson MJ. Simvastatin and side effects. New Zealand Med J 1991;104:493-5.[Medline]
5. Gaist D, Rodriguez LA, Huerta C, Hallas J, Sindrup SH. Lipid-lowering drugs and the risk of myopathy: a population-based follow-up study. Epidemiology 2001;12:565-9.[CrossRef][ISI][Medline]
6. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292:2585-90.[Abstract/Free Full Text]
7. Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 2005;165:2671-6.[Abstract/Free Full Text]
8. Westwood FR, Bigley A, Randall K, Marsden AM, Scott RC. Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity. Toxicol Pathol 2005;33:246-57.[Abstract/Free Full Text]
9. Baker SK. Molecular clues into the pathogenesis of statin mediated muscle toxicity. Muscle Nerve 2005;31:572-80.[CrossRef][ISI][Medline]
10. Paiva H, Thelen KM, Van Coster R, Smet J, De Paepe B, Mattila KM, et al. High-dose statins and skeletal muscle metabolism in humans: a randomized controlled trial. Clin Pharmacol Ther 2005;78:60-8.[CrossRef][ISI][Medline]
11. Laaksonen R, Jokelainen K, Sahi T, Tikkanen MJ, Himberg JJ. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther 1995;57:62-6.[CrossRef][ISI][Medline]
12. Dirks AJ, Jones KM. Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol 2006;291:1208-12.[CrossRef]
13. Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. Am J Cardiol 2006;97(suppl):69-76C.[CrossRef]
14. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Stroke 2002;33:2337-41.[Free Full Text]
15. Davidson MH, Robinson JG. Safety of aggressive lipid management. J Am Coll Cardiol 2007;49:1753-62.[Abstract/Free Full Text]
16. Vladutiu GD, Simmons Z, Isackson PJ, Tarnopolsky M, Peltier WL, Barboi AC, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006;34:153-62.[CrossRef][ISI][Medline]
17. Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 1997;46:1206-10.[CrossRef][ISI][Medline]
18. Rosenson RS. Current overview of statin-induced myopathy. Am J Med 2004;116:408-16.[CrossRef][ISI][Medline]
19. Keogh A, Macdonald P, Kaan A, Aboyoun C, Spratt P, Mundy J. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant 2000;19:529-37.[CrossRef][ISI][Medline]
20. Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol 2007;18:401-8.[CrossRef][ISI][Medline]
21. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;260:7-22.
22. Meltzer HY, Holy PA. Black-white differences in serum creatine phosphokinase (CPK) activity. Clin Chim Acta 1974;54:215-24.[CrossRef][ISI][Medline]
23. Rowland LP, Willner, J, DiMauro S, Miranda A. Approaches to the membrane theory of Duchenne muscular dystrophy. In: Angelini C, Danieli GA, Fontanari D, eds. Muscular dystrophy-advances and new trends. Amsterdam: Excerpta Medica, 1980:3-13.
24. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, et al. Statin-associated myopathy with normal creatine kinase. Ann Intern Med 2002;137:581-5.[Abstract/Free Full Text]
25. Tsivgoulis G, Spengos K, Karandreas N, Panas M, Kladi A, Manta P. Presymptomatic neuromuscular disorders disclosed following statin treatment. Arch Intern Med 2006;166:1519-24.[Abstract/Free Full Text]
26. Radcliffe KA, Campbell WW. Statin myopathy. Curr Neurol Neurosci Rep 2008;8:66-72.[CrossRef][ISI][Medline]
27. Draeger A, Monastyrskaya K, Mohaupt M, Hoppeler H, Savolainen H, Allemann C, et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol 2006;210:94-102.[CrossRef][ISI][Medline]
28. Baker SK, Samjoo IA. A neuromuscular approach to statin-related myotoxicity. Can J Neurol Sci 2008;35:8-21.[ISI][Medline]
29. Kelly P, Vaso S, Gelato M, McNurlan M, Lawson W. Coenzyme Q10 improves myopathic pain in statin treated patients [abstract]. J Am Coll Cardiol 2005;45(3 Suppl A):3A.